[Comparative double-blind study: alizapride-metoclopramide].
The anti-emetic action of alizapride was compared to that of metoclopramide in a strict double-blind study of 57 cases files derived from 21 patients treated with anti-mitotic chemotherapy. For each treatment, each patient received two ampoules before and after the chemotherapy. Each ampoule contained either 50 mg of alizapride or 10 mg of metoclopramide. There were 24 good or excellent results and 4 nil results with alizapride and 16 good or excellent results and 13 nil results with metoclopramide. The superiority of alizapride over metoclopramide was therefore established with statistical significance (0.05 greater than p greater than 0.02).
D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use*; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy
D000932:Antiemetics; D000970:Antineoplastic Agents; D011759:Pyrrolidines; D008787:Metoclopramide; C033968:alizapride
Etude comparative en double aveugle: alizapride-métoclopramide.